ENDPOINTS

Emergent sells once-troubled Baltimore site to Syngene

Emergent BioSolutions is selling a manufacturing site in Baltimore — which has a...

Federal judge denies preliminary injunction in tirzepat...

Compounding pharmacies faced a major setback in their case over the FDA’s decisi...

Emergent sells once troubled Baltimore site to Syngene

Emergent is selling a manufacturing site in Baltimore — which has a history of c...

Beam shares promising first clinical data on gene editi...

Beam Therapeutics said its experimental gene editing treatment helped lower leve...

#AAD25 roundup: Data from Amgen, Bristol Myers, J&J, Al...

At this year’s American Academy of Dermatology annual meeting, companies like Am...

FDA blocks drug and device reviewers from taking HHS' b...

The FDA told staff on Monday that reviewers of medical products and inspectors o...

Mired in low expectations, Novo braces for upcoming Cag...

Novo Nordisk’s late-stage weight loss data showed CagriSema performed below anal...

J&J, Protagonist outline first IBD win for potential im...

Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug wi...

Trevi Therapeutics stock soars on Phase 2a chronic coug...

Trevi Therapeutics’ chronic cough drug reduced patients’ 24-hour cough frequency...

Arrowhead reveals small batch of open-label data for 'n...

Arrowhead Pharmaceuticals on Monday shared new open-label data in about a dozen ...

Exclusive: RNA delivery startup strikes partnerships wi...

Nosis Bio, a startup developing new ways to deliver RNA therapies to specific ce...

Novo Nordisk’s CagriSema shows 15.7% weight loss in sec...

Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both...

Sun Pharma to acquire Checkpoint Therapeutics and its a...

After months of searching for a partner for its recently approved cancer drug, C...

Mineralys’ Phase 3 blood pressure pill data support pot...

Topline pivotal data suggest that Mineralys Therapeutics’ experimental hypertens...

Exclusive: RNA delivery startup strikes partnerships wi...

Nosis Bio, a startup developing new ways to deliver RNA therapies to specific ce...

FDA and NIH nominees sail through Senate hearings; Tari...

Welcome back to Endpoints Weekly! This week was another busy one in DC, with two...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.